Eli Lilly Halts Trial For COVID-19 Treatment On Hospitalized Patients

Samantha Horton

Article origination IPBS-RJC

Eli Lilly Corporate Headquarters in Indianapolis.
*Lauren Chapman/IPB News*

Indianapolis-based Eli Lilly has ended testing its COVID-19 antibody therapy on hospitalized patients. Earlier this month, Eli Lilly temporarily suspended the trial for the drug due to a safety concern.

In a news release, the company said recent data showed there wasn’t a significant difference in outcomes for COVID-19 patients in advanced stages who received the treatment compared to those who did not.

The trial was evaluating recovery chances for severe cases when the drug was administered in combination with an antiviral medication that was recently approved by the Food and Drug Administration.

This study was being done in partnership with the National Institute of Allergy and Infectious Diseases and that was the only one testing bamlanivimab in COVID-19 hospitalized patients.

The pharmaceutical company will continue trials of the drug in other settings including nursing homes.

Contact reporter Samantha at shorton@wfyi.org or follow her on Twitter at @SamHorton5.

Tags:Eli Lilly and Co.pharmaceuticals coronavirus COVID-19

Support independent journalism today. You rely on WFYI to stay informed, and we depend on you to make our work possible. Donate to power our nonprofit reporting today. Give now.

Indiana not among ten worst infant mortality rates in the country for the first time since 2019

Indiana’s infant mortality rate improved in 2023. Provisional data from the Centers for Disease Control and Prevention shows Indiana is no longer among the ten worst states.